Evaluating multi-cancer early detection tests: an argument for the outcome of recurrence-updated stage

Matthew E.J. Callister, Emma J. Crosbie, Philip A.J. Crosbie, Hilary A. Robbins

Research output: Contribution to journalArticlepeer-review

Abstract

The advent of multi-cancer early detection (MCED) tests has the potential to revolutionise the diagnosis of cancer, improving patient outcomes through early diagnosis and increased use of curative therapies. The ongoing NHS-Galleri trial is evaluating an MCED test developed by GRAIL, and is using as its primary endpoint the absolute incidence of late-stage cancer. Proponents of this outcome argue that if the test reduces the number of patients with advanced, incurable cancer, it can be reasonably assumed to be benefitting patients by reducing cancer mortality. Here, we argue that this assumption may not always hold due to the phenomenon of micro-metastatic disease, and propose an adjustment to the trial outcome so that it may better reflect the expected effect of the test on cancer mortality.

Original languageEnglish
Pages (from-to)1209-1211
Number of pages3
JournalBritish Journal of Cancer
Volume129
Issue number8
Early online date19 Sept 2023
DOIs
Publication statusPublished - 12 Oct 2023

Keywords

  • Humans
  • Early Detection of Cancer
  • Neoplasms/diagnosis
  • Neoplasms, Second Primary

Fingerprint

Dive into the research topics of 'Evaluating multi-cancer early detection tests: an argument for the outcome of recurrence-updated stage'. Together they form a unique fingerprint.

Cite this